ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
Get Alerts IMGN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
-
William Blair 42nd Annual Growth Stock Conference
June 8 at 11:20am CT / 12:20pm ET
-
Jefferies Healthcare Conference
June 9 at 9:30am ET
A webcast of each presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005263/en/
INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
[email protected]
OR
FTI Consulting
Robert Stanislaro
212-850-5657
[email protected]
Source: ImmunoGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marqeta Partners with OakNorth to Offer Commercial Cards in the UK, Embracing Growing Small and Medium-Sized Business Demand for Better Banking Tools
- WOO X Lists $CKB on its Spot Market
- The Missing Piece - TUC s.r.l presents TUC.tiny: the key to access New Mobility
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
William Blair, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!